Clinical Trial Update: Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy [Phase 2, Phase 3]

View source ↗

Summary

An open-label Phase 2/3 trial comparing AAA817 to standard of care in PSMA-positive metastatic castration-resistant prostate cancer that progressed after Lu-PSM…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• AAA817

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Prostate Cancer | Phase 2, Phase 3 | Status: RECRUITING